Abstract
Objective: To analyze the clinical characteristics of abnormal personality and conduct disorders (CDs) in pediatric patients with vasovagal syncope (VVS).Methods: In this study, we recruited patients diagnosed with VVS at Children's Heart Center from January 2018 to December 2020. Healthy children were recruited as controls. The Eysenck Personality Questionnaire-Child edition (EPQ-C) and Achenbach Child Behavior Checklist (CBCL) were used for the assessment.Results: One hundred and fifty-one VVS patients and 151 healthy controls were included in this study. Compared with the control group, patients in the VVS group had a higher incidence of abnormal personality and were more prone to suffer from CDs. Moreover, pediatric patients with VVS suffered more events of syncope recurrence if they had CDs.Conclusion: Abnormal personality and CDs are common clinical characteristics in pediatric patients with VVS.
Highlights
Vasovagal syncope (VVS) is the most frequently reported clinical sub-type of neurally mediated syncope [1]
We enrolled patients who were diagnosed with VVS, based on the 2018 Chinese Pediatric Cardiology Society (CPCS) guidelines, and admitted at the Children’s Heart Center, West China Second University Hospital, Sichuan University from January 2018 to December 2020
The findings suggest that pediatric patients with VVS suffered more events of syncope recurrence, if they had conduct disorders (CDs) (P < 0.05)
Summary
Vasovagal syncope (VVS) is the most frequently reported clinical sub-type of neurally mediated syncope [1]. Vasovagal syncope is classically characterized by specific forms of acute orthostatic intolerance, recurrent syncope, and spontaneous remission [3]. Most of the pediatric patients with VVS could have favorable prognosis with less somatic discomfort and cerebral hypoperfusion events after classic treatment, the recurrence rate of VVS still remains high, which was recently reported with a 1-year recurrence rate of 30% [5]. Classic treatments for pediatric patients with VVS include conventional treatment, peripheral alpha-receptor agonists, and traditional beta-blockers, etc. These treatments experience the bottleneck while further reduction of VVS recurrence
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
